VETORYL® Capsules — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

VETORYL® Capsules

Active ingredient

Trilostane

Application type

NADA

Sponsor

Dechra Veterinary Products LLC

Applications on record

1

First published

July 14, 2026

Adverse event reports

Source: openFDA VeDDRA

11,986

Reports mentioning this ingredient

April 5, 2004 – March 23, 2026

5,425

Classified serious

per reporter assessment

1,657

Lack of expected efficacy

resistance signal

63

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “TRILOSTANE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Lethargy (see also Central nervous system depression in 'Neurological')	1,898
Vomiting	1,881
Hyperkalaemia	1,665
Elevated serum alkaline phosphatase (SAP)	1,621
Underdose	1,418
Weight loss	1,389
Diarrhoea	1,339
Elevated alanine aminotransferase (ALT)	1,285
Anorexia	1,049
Elevated blood urea nitrogen (BUN)	1,049
Decreased appetite	1,026
INEFFECTIVE, CUSHINGS	965
Death by euthanasia	835
Abnormal adrenocorticotropic hormone (ACTH) stimulation test	798
Low sodium-potassium ratio (Na:K ratio)	786
Other abnormal test result NOS	782
Polydipsia	780
Polyuria	696
Hypoadrenocorticism	675
Decreased urine concentration	619

Species affected

Source: openFDA VeDDRA

Dog 11,705 Human 46 Cat 10 Horse 1 Other 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient